Zacks Industry Outlook Highlights: Johnson & Johnson, Forest Labs, Biogen, Amgen and Medivation

  Zacks Industry Outlook Highlights: Johnson & Johnson, Forest Labs, Biogen,
                             Amgen and Medivation

PR Newswire

CHICAGO, July 31, 2013

CHICAGO, July 31, 2013 /PRNewswire/ --Today, Zacks Equity Research discusses
the U.S. Pharma & Biotech, including Johnson & Johnson (NYSE:JNJ-Free Report),
Forest Labs (NYSE:FRX-Free Report), Biogen (Nasdaq:BIIB-Free Report), Amgen
(Nasdaq:AMGN-Free Report) and Medivation (Nasdaq:MDVN-Free Report).


Industry: Pharma & Biotech


While several companies will continue to face challenges like EU austerity
measures and genericization, the pharma industry should be out of the worst of
the genericization phase from 2013. Many companies which had faced generic
headwinds in the last couple of years should see their results improve from
2013. Cost-cutting, downsizing, streamlining of the pipeline, growth in
emerging markets and product approvals should support growth.

Among large-cap pharma stocks,Johnson & Johnson (NYSE:JNJ-Free Report)
currently holds a Zacks Rank #2 (Buy). The company has performed well in the
first half of 2013 and the momentum should continue through the remainder of
the year. The company has been trying to offset the declining sales of some of
its important products by bringing in new products through in-licensing deals
and acquisitions. We believe the diversity and strength of the company's
underlying businesses will continue to provide strong growth in future. The
Synthes deal should continue driving results.

Forest Labs (NYSE:FRX-Free Report), another Zacks Rank #2 stock, is doing well
with first quarter fiscal 2014 results beating expectations. The company has
launched several new products over the past few quarters and continues to make
impressive progress with its pipeline.

In the biotech space, we are positive on Biogen (Nasdaq:BIIB-Free Report).
Tecfidera, the company's recently launched oral multiple sclerosis drug, is
off to a strong start with launch quarter sales coming in at $192 million
(including inventory stocking of $82 million). While Tecfidera has the
potential to gain the top spot in the oral multiple sclerosis market, Avonex
and Tysabri should continue contributing significantly to sales. Biogen is
also progressing with its hemophilia pipeline.

We are also positive on Amgen (Nasdaq:AMGN-Free Report). Amgen should be able
to deliver on its long-term strategy based on expansion in key markets, launch
of new manufacturing technologies, and pipeline development. Enbrel should
continue performing well. Amgen's late-stage pipeline is also moving along.
While Amgen is a Zacks Rank #2 stock, Biogen is a Zacks Rank #3 (Hold) stock.
Gilead, another Zacks Rank #2 stock, continues to do well in the HIV segment
and is also progressing with its HCV pipeline.

Medivation (Nasdaq:MDVN-Free Report), a Zacks Rank #1 (Strong Buy) company,
should continue delivering with its prostate cancer therapy, Xtandi,
performing well. Based on the data we have seen so far, we believe Xtandi has
blockbuster potential. It is currently in several studies including for the
pre-chemo setting. Expansion into the pre-chemo setting would be a major
positive for Medivation.

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Click here for your free subscription to Profit from
the Pros.

Get the full Report on JNJ - FREE

Get the full Report on FRX - FREE

Get the full Report on BIIB - FREE

Get the full Report on AMGN - FREE

Get the full Report on MDVN - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities
(including a broker-dealer and an investment adviser), which may engage in
transactions involving the foregoing securities for the clients of such

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers
displayed in this press release.

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.